Utility of myeloperoxidase in the differential diagnosis of acute coronary syndrome

Objectives: To determine the usefulness of myeloperoxidase in discriminating between patients Acute coronary with acute coronary syndrome and patients with chest pain by other causes. Methods: The study included all patients over 18 years of age who come consecutively to Unstable angina; the emergency department from September 2015 to December 2015 with chest pain of non- Emergency traumatic origin. The initial patient evaluation was performed according to the study protocol department; for patients with suspected acute coronary syndrome (ACS) in our Emergency Department. Chest pain; This included the serial measurement of troponin, and in this case myeloperoxidase, with serialization on admission and at 6 h. For the determination of myeloperoxidase (MPO), a single step sandwich enzyme immunoassay by Siemens, automated on a Dimension analyser, was used. Results: Statistically significant differences were observed in the concentration of myeloperoxidase at time 0 among patients diagnosed with ACS: 505 (413) pmol/L, and non-ACS patients: 388 (195) pmol/L (p < .001), as well as at 6h (p < .001). An area under the curve ROC of 0.824 was obtained at 6 h for ACS patients, with a confidence interval of 95% from 0.715 to 0.933 and a level of significance of p < .001. Statistically significant differences were also found in the concentration of myeloperoxidase at time 0 and at 6 h among patients with ACS and patients with heart disease other than coronary artery disease. Conclusions: The concentration of MPO helps to differentiate between ACS and non-ACS patients, as well as between ACS patients and patients with heart diseases other than coronary artery disease. (C) 2017 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S.A.